Best of Global Cardio-Oncology Summit 2024
The Global Cardio-Oncology Summit 2024 took place in Minneapolis, Minnesota, from September 22-24.
The event gathered experts in cardiology and oncology to discuss critical topics related to the cardiovascular health of cancer patients. Participants had the opportunity to engage with the latest research, explore contemporary strategies for prevention, early diagnosis, and management of cardiovascular diseases in this patient population.
The summit fostered networking and collaboration among professionals, with presentations designed to encourage interaction between speakers and attendees.
Hosted by the Lillehei Heart Institute and the Masonic Cancer Center at the University of Minnesota, the summit was a significant event for advancing the field of cardio-oncology.
Here are some highlights from Global Cardio-Oncology Summit 2024:
International Cardio-Oncology Society:
“Congrats to the 2024 Thomas Force Pioneer Award winner, Dr Steven Lipshultz!
Dr Lipshultz is a dedicated pediatric cardio-oncologist who has helped protect the hearts of many children.”
“Attending the GCOS 2024 was a fantastic opportunity to connect with mentors and learn about the latest in Cardio-Oncology. Engaging discussions and insightful presentations enhanced my understanding of this evolving field.”
“Cezar Iliescu described by Joerg Herrmann as a ‘fighter pilot of intervention transversing cancer and cardiology’ describes pericardial drainage. Read his detailed article in JACC Journals.”
“Dr Bergom from Wash University discussing radiation induced cardiac toxicity.
Franciscan Health has developed a focused nurse navigator led pathway to help address these issues.”
“Anita Deswal giving her take on permissive cardiotoxicity at GCOS2024.”
“Dr. Tiffany Powell-Wiley highlighting the racial, gender and socio-economic disparities in Cardio-Oncology, outcomes, cardiotoxicity, and treatment interruption. Raises the importance of including a wider variety of patients in clinical trials.”
“My fav talk title so far!
Mike Fradley great take points:
1. AF is common, specially on BTKi and immunotherapy
2. Cancer patients are often not receiving guideline directed anticoag.
3. CHADSVASC May not be accurate in cancer patients
4. Blood risk and drug interactions limit aco in AF.”
“Very informative session on Disparities in Cardio-Oncology by Dr. Tiffany Powell-Wiley, Andreas Beyer, and Dr. Bonnie Ky.”
“Congrats Aom Osataphan on your excellent presentation and winning the Young Investigator Awards at GCOS2024 on the development of CTRCD and Diastolic dysfn in 5 year follow up after cancer therapy in HER2+ breast cancer patients.”
“Session 2 iPSC application in cardio-oncology. Dr. Mozneb giving an excellent talk regarding their heart on the chip study!”
“Nurses are the key for Cardio-Oncology. Great leadership by Kerry Skurka.”
“Hats off to Zip Wake Forest University T32 fellow for presenting her poster on endocrine therapy + cdk4/6 inhibitor cardiotoxicity study at GCOS24.”
“Thrilled to present our abstract at GCOS24 on behalf of the Brompton Cardio-Oncology team.
CV adverse events in thyroid cancer patients treated with selective RET inhibitors.”
International Cardio-Oncology Society:
“Day 3 of GCOS2024 is here!
Anne Blaes and Suma Konety MD, MS kick us off, followed by Alexander Lyon, MD, PhD in his keynote on Immune Checkpoint Inhibitor-Associated Myocarditis. See Today’s Schedule.
Share your favorite moments with GCOS2024!”
Stay tuned by visiting oncodaily.com
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023